Goldman Sachs analyst Andrea Tan raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $51 from $45 and keeps a Neutral rating on the shares.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Tarsus Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- Tarsus Pharmaceuticals: Strong Market Performance and Growth Potential Justify Buy Rating
- Strong Market Position and Growth Potential Drive Buy Rating for Tarsus Pharmaceuticals
- Tarsus Pharmaceuticals Reports Strong Q3 2025 Growth
- Tarsus Pharmaceuticals: Strong Financial Performance and Strategic Growth Justify Buy Rating